Tag Archive | "Encorafenib plus binimetinib"

Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma

Source: Healio, June 2018

Combination therapy with encorafenib plus binimetinib significantly improved OS compared with vemurafenib or encorafenib alone for patients with advanced BRAF-mutated melanoma, according to phase 3 results from the COLUMBUS trial presented at ASCO Annual Meeting.
Encorafenib (LGX818, Array BioPharma) plus binimetinib (MEK162, Array BioPharma) — a BRAF/MEK inhibitor combination — conferred a best-in-class median PFS of 14.9 months and median OS of 33.6 months. In comparison, vemurafenib (Zelboraf, Genentech) monotherapy conferred a median PFS of 7.3 months and median OS of 16.9 months, and encorafenib monotherapy conferred a median PFS of 9.6 months and median OS of 23.5 months.
“Encorafenib plus binimetinib combination therapy provides a new efficacy benchmark for targeted therapy and it is a promising treatment option for patients with BRAFV600-mutant melanoma,” Reinhard Dummer, MD, from the department of dermatology at University of Zurich Hospital in Zurich, Switzerland, said during his presentation.
read the original full article

Posted in Melanoma News, Clinical TrialsComments Off on Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma